CREB1 and BDNF gene polymorphisms are associated with early treatment response to escitalopram in panic disorder

• Published in: Journal of affective disorders Vol. 278; pp. 536 - 541
• Main Authors: Yang, Junfeng, Li, Shen, Lv, Hao, Wang, Wenchen, Zhang, Jian, Chu, Lijun, Zhang, Yong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2021
• Subjects: Asian Continental Ancestry Group; BDNF; Brain-Derived Neurotrophic Factor - genetics; Citalopram - therapeutic use; CREB1; Cyclic AMP Response Element-Binding Protein - genetics; Escitalopram; Humans; Panic disorder; Panic Disorder - drug therapy; Panic Disorder - genetics; Polymorphism, Single Nucleotide - genetics; SNP; CREB1; SNP; BDNF; Escitalopram; Panic disorder
• ISSN: 0165-0327; 1573-2517
• DOI: 10.1016/j.jad.2020.09.076

•CREB1 and BDNF gene polymorphisms are associated with rapid efficacy to escitalopram on PD patients.•First explore quantitative and binary associations between SNPs and escitalopram treatment response.•PD patients with CREB1 rs11904814TT genotype and rs2551941 AA genotype have better treatment response. Increasing evidence shows that the alternations under escitalopram treatment for Panic disorder (PD) patients are related to the cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF). We aimed to explore the single nucleotide polymorphisms (SNPs) of genes BDNF and CREB1 in the treatment response to escitalopram on PD. There were 80 PD patients with DSM-5 diagnosis and 78 healthy controls. All PD patients have received escitalopram treatment for consecutive 8 weeks. The Chinese version of Panic Disorder Severity Scale (PDSS-CV) and the Hamilton Anxiety Scale (HAMA-14) were used to evaluate the severity of panic and anxious symptoms for PD patients at baseline, week-2, week-4, and week-8, respectively. Four SNPs (rs11904814, rs6740584, rs2253206, and rs2551941) in CREB1 gene and rs6265 in BDNF gene were genotyped using matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS). Quantitative and binary genetic associations between SNPs and escitalopram treatment response were performed. The comparisons of three genotypes in CREB1 SNPs rs11904814 and rs2551941 among the PDSS-CV responders showed significant differences at the end of week-2 (both p<0.05). The results remained significant after Bonferroni corrections. For candidate genes in our present study, the gene CREB1 SNP rs11904814 (p=0.007) was significantly associated with changes of PDSS-CV scores under escitalopram treatment for 12 weeks in PD patients. And the result was still significant after adjusting age and gender. The findings provide preliminary evidence supporting the potential role of BDNF and CREB1 on a rapid response after escitalopram intervention in PD patients.